Quercetin for Coronary Artery Disease

(Q-CABG Trial)

Overseen By Michel Carrier, MD

Age: 18+

Sex: Any

Trial Phase: Phase 2

Sponsor: Montreal Heart Institute

Must not be taking: Quinolone, Quercetin

Disqualifiers: Renal insufficiency, Liver disease, Cirrhosis, others

Prior Safety Data This treatment has passed at least one previous human trial

Approved in 1 Jurisdiction This treatment is already approved in other countries

Compensation: Varies

Number of Visits: 2

100 Participants Needed

Trial Summary

Will I have to stop taking my current medications?

The trial does not specify if you need to stop taking your current medications, but you cannot participate if you are taking quinolone antibiotics or quercetin supplements.

What evidence supports the effectiveness of the treatment Quercetin for Coronary Artery Disease?

Research suggests that quercetin, a natural compound found in many fruits and vegetables, has antioxidant and anti-inflammatory properties that may help manage conditions like atherosclerosis (a disease where plaque builds up in the arteries). While quercetin significantly increases its levels in the blood, studies have not shown it to directly affect heart disease risk factors in healthy individuals. ^{1 2 3 4 5}

Is quercetin safe for human use?

Research on flavonoids, including quercetin, suggests they generally have low toxicity in human cell studies, indicating they are likely safe for human use. However, the safety of quercetin specifically for coronary artery disease has not been directly addressed in the provided studies. ^{6 7 8 9 10}

How is the drug quercetin unique in treating coronary artery disease?

Quercetin is unique because it has antioxidant and anti-inflammatory properties that help protect the heart by improving blood flow, reducing heart rhythm issues, and limiting heart damage during a heart attack. It also helps maintain the integrity of blood vessels, which can prevent blood clots and improve overall heart function. ^{3 11 12 13 14}

What is the purpose of this trial?

This trial is testing quercetin, a natural substance found in fruits and vegetables, to see if it can reduce inflammation and slow down aging cells in patients undergoing heart bypass surgery. Patients will take quercetin starting before their surgery and continue for a short period afterward. The study will measure inflammation and cell health through blood samples. Quercetin is known for its antioxidant, anti-inflammatory, and cardio-protective properties.

Research Team

Michel Carrier, MD

Principal Investigator

Montreal Heart Institute

Eligibility Criteria

This trial is for adults who've had a heart attack in the last 30 days or have stable angina, awaiting coronary artery bypass surgery. They must speak French or English and consent to participate. Excluded are those without recent heart attacks, with infections, severe kidney/liver disease, estrogen-dependent tumor history, flavonoid intolerance, or taking certain medications.

Inclusion Criteria

I had a heart attack in the last 30 days or my chest pain is stable.

To be able to give free and enlighten consent

I am hospitalized and waiting for heart bypass surgery.

Exclusion Criteria

I have had breast cancer or another estrogen-dependent tumor before.

You are unable to tolerate flavonoids, niacin, or ascorbic acid.

I am currently taking a quinolone medication.

Timeline

Screening

Participants are screened for eligibility to participate in the trial

1-2 weeks

Pre-surgery Treatment

Participants receive quercetin or placebo starting 2 days before surgery

2 days

1 visit (in-person)

Surgery and Immediate Post-surgery

Participants undergo coronary artery by-pass graft surgery and receive treatment during hospitalization

Up to 10 days

In-patient stay

Follow-up

Participants are monitored for health status and changes post-surgery

8 to 12 weeks

1 visit (in-person)

Treatment Details

Interventions

• Quercetin

Trial Overview The study examines Quercetin's potential to reduce inflammation and slow cell aging during coronary bypass surgery compared to a placebo. Participants will be randomly assigned to receive either Quercetin or an inactive substance.

Participant Groups

Group I: Quercetin Active Control 1 Intervention

Patients receiving 500 mg quercetin twice daily

Group II: Placebo Placebo Group 1 Intervention

Patients receiving placebo twice daily

Quercetin is already approved in United States for the following indications:

Approved in United States as Quercetin for:

• Herbal Supplementation
• Nonbacterial Chronic Prostatitis
• Interstitial Cystitis

Who Is Running the Clinical Trial?

Montreal Heart Institute

Lead Sponsor

Trials

125

Recruited

85,400+

References

1. United States pubmed.ncbi.nlm.nih.gov

Supplementation with quercetin markedly increases plasma quercetin concentration without effect on selected risk factors for heart disease in healthy subjects. [2021]

2. Netherlands pubmed.ncbi.nlm.nih.gov

Effect of quercetin on traits of the metabolic syndrome, endothelial function and inflammation in men with different APOE isoforms. [2022]

3. England pubmed.ncbi.nlm.nih.gov

Citrus flavonoids and adhesion molecules: Potential role in the management of atherosclerosis. [2023]

4. Iran pubmed.ncbi.nlm.nih.gov

The effect of quercetin on plasma oxidative status, C-reactive protein and blood pressure in women with rheumatoid arthritis. [2022]

5. Switzerland pubmed.ncbi.nlm.nih.gov

Isoquercitrin Esters with Mono- or Dicarboxylic Acids: Enzymatic Preparation and Properties. [2018]

6. England pubmed.ncbi.nlm.nih.gov

Effects of several flavonoids on the growth of B16F10 and SK-MEL-1 melanoma cell lines: relationship between structure and activity. [2019]

7. Germany pubmed.ncbi.nlm.nih.gov

The inhibitory effects of 5-hydroxy-3,6,7,8,3',4'-hexamethoxyflavone on human colon cancer cells. [2022]

8. United States pubmed.ncbi.nlm.nih.gov

Citrus Flavanones Enhance β-Carotene Uptake in Vitro Experiment Using Caco-2 Cell: Structure-Activity Relationship and Molecular Mechanisms. [2019]

9. England pubmed.ncbi.nlm.nih.gov

Antiproliferative activity of flavonoids on several cancer cell lines. [2022]

10. Switzerland pubmed.ncbi.nlm.nih.gov

Analysis of Citrus Bioflavonoid Content and Dipeptidyl Peptidase-4 Inhibitory Potential of Commercially Available Supplements. [2022]

11. Russia (Federation) pubmed.ncbi.nlm.nih.gov

[The cardioprotective action of quercetin in experimental occlusion and reperfusion of the coronary artery in dogs]. [2013]

12. Netherlands pubmed.ncbi.nlm.nih.gov

Impact of quercetin in patients with myocardial infarction. A multicenter, randomized, open label pilot study. [2023]

13. Russia (Federation) pubmed.ncbi.nlm.nih.gov

[The effect of the 5-lipoxygenase inhibitor quercetin on the functional and morphologic manifestations of myocardial lesions in ischemia and reperfusion of the heart]. [2017]

14. Turkey pubmed.ncbi.nlm.nih.gov

Dietary polyphenol quercetin protects rat hearts during reperfusion: enhanced antioxidant capacity with chronic treatment. [2013]